Literature DB >> 27519817

Acute Alpha-Naphthylisothiocyanate-induced Liver Toxicity in Germfree and Conventional Male Rats.

John M Cullen1, Brenda Faiola2, David H Melich2, Richard A Peterson2, Holly L Jordan2, Carie L Kimbrough3, Richard T Miller2.   

Abstract

Differences in the responses of conventional and germfree male Sprague-Dawley rats to acute injury induced by alpha-naphthylisothiocyanate (ANIT), a well-characterized biliary epithelial toxicant, were evaluated. Conventional and germfree rats were dosed once orally with 50 mg/kg of ANIT or corn oil alone and serially sacrificed daily for the next 3 days. Germfree rats treated with ANIT tended to have greater increases in virtually all liver and biliary-related analytes compared with conventional rats treated with ANIT; however, significant differences were found only in a few of these analytes including increased bile acids on day 3, total bilirubin on day 4, glutamate dehydrogenase (GLDH) on day 3, and reduced paraoxonase 1 (PON1) on days 2 and 3. Histologic differences between the conventional and germfree rats were modest, but most pronounced on day 2 (24-hr post dosing). Based on subjective scoring, biliary necrosis, neutrophilic cholangitis, and portal tract edema were more severe in germfree rats at 24 hr post dosing compared with conventional rats. Biliary epithelial replication did not differ between treated groups, however. Overall, germfree rats had a modestly greater level of biliary tract injury based on subjective histologic scoring and clinical chemistry measurements following an acute exposure to the well-characterized biliary toxin, ANIT; however, the difference between the ANIT-treated germfree and conventional groups was modest and most evident only within the first day following exposure. These findings suggest that the microbiome did not significantly affect ANIT-induced acute biliary tract injury in the conditions of this study.
© The Author(s) 2016.

Entities:  

Keywords:  alpha-naphthylisothiocyanate; bile duct; germfree; liver; rat; toxicity

Mesh:

Substances:

Year:  2016        PMID: 27519817     DOI: 10.1177/0192623316662360

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  6 in total

Review 1.  Effects of Melatonin on Liver Injuries and Diseases.

Authors:  Jiao-Jiao Zhang; Xiao Meng; Ya Li; Yue Zhou; Dong-Ping Xu; Sha Li; Hua-Bin Li
Journal:  Int J Mol Sci       Date:  2017-03-23       Impact factor: 5.923

2.  Investigating the cause of Brassica-associated liver disease (BALD) in cattle: Progoitrin-derived nitrile toxicosis in rats.

Authors:  Zoe M Matthews; Kathleen H Parton; Mark G Collett
Journal:  Toxicon X       Date:  2019-12-30

3.  Effect of Different Ratios of Yinchen and Gancao Decoction on ANIT-Treated Cholestatic Liver Injury in Mice and Its Potential Underlying Mechanism.

Authors:  Huizong Su; Qian Wang; Yue Li; Jingyi Jin; Bo Tan; Dongming Yan; Bin Zou; Guochao Song; Fengyi Weng; Furong Qiu
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

4.  Targeted bile acid profiles reveal the liver injury amelioration of Da-Chai-Hu decoction against ANIT- and BDL-induced cholestasis.

Authors:  YueHua Zhou; YunZhong Zhou; YiFei Li; Wei Sun; ZhaoLong Wang; Long Chen; Ye He; XiaoLong Niu; Jialiang Chen; Guangtao Yao
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988

5.  Identification of potential biomarkers in cholestasis and the therapeutic effect of melatonin by metabolomics, multivariate data and pathway analyses.

Authors:  Han Yu; Yunzhou Li; Zongying Xu; Dingnan Wang; Shaohua Shi; Huifang Deng; Baihui Zeng; Zhili Zheng; Lili Sun; Xiulan Deng; Xianggen Zhong
Journal:  Int J Mol Med       Date:  2018-09-05       Impact factor: 4.101

6.  LCAT protects against Lipoprotein-X formation in a murine model of drug-induced intrahepatic cholestasis.

Authors:  Marcelo J A Amar; Lita A Freeman; Takafumi Nishida; Maureen L Sampson; Milton Pryor; Boris L Vaisman; Edward B Neufeld; Sotirios K Karathanasis; Alan T Remaley
Journal:  Pharmacol Res Perspect       Date:  2019-12-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.